1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Multiple due dates: 2/21/2025, 6/20/2025, 2/20/2026, 6/22/2026 (final). All due by 5:00 PM local time of applicant organization. FOA updated 3/31/2025 to align with agency priorities.
"Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development" is currently closed and not accepting applications.
Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development is sponsored by National Institutes of Health (NIH). Supports development of biomarkers or clinical outcomes from digital health technology for remote monitoring in clinical trials.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Opportunity Listing - Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional) Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development (UG3/UH3 - Clinical Trial Optional) Agency: National Institutes of Health Assistance Listings: 93. 866 -- Aging Research 93.
853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders Last Updated: May 13, 2026 View version history on Grants. gov The purpose of this proposed Notice of Funding Announcement (NOFO) is to support development of biomarkers or clinical outcomes derived from digital health technology (DHT) for use in clinical trials for remote monitoring as primary or secondary endpoints.
To improve clinical impact, increase statistical feasibility, and promote standardization, applicants will be expected to develop and test the digitally derived assessments in populations from at least three different diseases or conditions. Partnerships with non-profit patient advocacy organizations will be required.
Nonprofits non-higher education without 501(c)(3) Other Native American tribal organizations Nonprofits non-higher education with 501(c)(3) For-profit organizations other than small businesses Public and Indian housing authorities City or township governments Special district governments Federally recognized Native American tribal governments Independent school districts Public and state institutions of higher education Private institutions of higher education Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Grantor contact information See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
File name Description Last updated PAR-25-170-Full-Announcement. html PAR-25-170 Full Announcement Text Nov 13, 2024 03:21 PM UTC Link to additional information https://grants. nih.
gov/grants/guide/pa-files/PAR-25-170. html Funding opportunity number : Cost sharing or matching requirement : Funding instrument type : Opportunity Category Explanation : Category of Funding Activity : Your account requires additional identity verification.
Key questions and narrative sections extracted from the solicitation.
DHT biomarker/COA development plan
3+ disease/condition scope
People with lived experience engagement plan
Phase 1: technical performance evaluation
Phase 2: prospective longitudinal clinical study
Data management and sharing plan
Genomic data sharing plan (if applicable)
According to the current listing, eligibility includes: U. S. organizations, both private and public. Confirm the full requirements in the official notice before applying.
Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development accepts applications on a rolling basis — there is no single fixed deadline. Check the official notice for any cycle-specific review dates.
Digital Health Technology Derived Biomarkers and Outcome Assessments for Remote Monitoring and Endpoint Development is funded by National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
The solicitation lists 5 required documents: Project narrative, Budget and justification, Biosketches, Facilities and resources, and Data management plan. Check the official notice for formatting and page-limit rules.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article